• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项评估单次剂量倍他洛尔β-肾上腺素受体选择性的剂量范围研究。

A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol.

作者信息

Irvine N A, Lipworth B J, McDevitt D G

机构信息

Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland.

出版信息

Br J Clin Pharmacol. 1990 Jul;30(1):119-26. doi: 10.1111/j.1365-2125.1990.tb03751.x.

DOI:10.1111/j.1365-2125.1990.tb03751.x
PMID:1975196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1368283/
Abstract
  1. Six normal subjects were given single oral doses of betaxolol 10 mg (B10), 20 mg (B20), 40 mg (B40), 80 mg (B80), propranolol 40 mg (P40), or placebo (PL) in a single-blind randomised cross-over design. 2. beta 1-adrenoceptor blockade was assessed by reductions in exercise heart rate. Betaxolol produced dose-related reductions in exercise heart rate (beats min-1) up to a ceiling at B40, after which B80 showed a lesser effect: (158 +/- 8 PL, 128 +/- 3 B10, 123 +/- 2 B20, 116 +/- 4 B40, 136 +/- 10 B80, 135 +/- 4 P40). All doses of betaxolol (except B80) produced greater reductions compared with P40: (B10 P less than 0.001, B20 P less than 0.005, B40 P less than 0.001). 3. beta 2-adrenoceptor blockade was assessed by attenuation of finger tremor and cardiovascular responses to graded infusions of i.v. isoprenaline. Dose-response curves were constructed and the doses required to increase heart rate by 25 beats min-1, finger tremor by 200%, calf blood flow by 0.5 ml dl-1 min-1, and decrease diastolic blood pressure by 10 mm Hg, after each treatment were calculated. These were then compared with placebo responses and expressed as dose-ratios. 4. Dose-ratios for finger tremor showed significant attenuation by all doses of betaxolol (compared with PL): B10 1.5 +/- 0.18 (P less than 0.05), B20 2.62 +/- 0.45 (P less than 0.005), B40 2.55 +/- 0.33 (P less than 0.001), B80 2.48 +/- 0.48 (P less than 0.01); and by P40 6.49 +/- 1.12 (P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 六名正常受试者采用单盲随机交叉设计,分别单次口服10毫克(B10)、20毫克(B20)、40毫克(B40)、80毫克(B80)倍他洛尔,40毫克普萘洛尔(P40)或安慰剂(PL)。2. 通过运动心率降低评估β1肾上腺素能受体阻滞情况。倍他洛尔使运动心率(次/分钟)呈剂量依赖性降低,直至B40达到峰值,此后B80效果减弱:(安慰剂组158±8,B10组128±3,B20组123±2,B40组116±4,B80组136±10,P40组135±4)。与P40相比,所有剂量的倍他洛尔(B80除外)均使运动心率降低更显著:(B10,P<0.001;B20,P<0.005;B40,P<0.001)。3. 通过减轻手指震颤以及对静脉注射异丙肾上腺素分级输注的心血管反应来评估β2肾上腺素能受体阻滞情况。绘制剂量反应曲线,并计算每次治疗后使心率增加25次/分钟、手指震颤增加200%、小腿血流量增加0.5毫升/分升/分钟以及舒张压降低10毫米汞柱所需的剂量。然后将这些剂量与安慰剂反应进行比较,并以剂量比表示。4. 所有剂量的倍他洛尔(与安慰剂相比)均使手指震颤的剂量比显著降低:B10为1.5±0.18(P<0.05),B20为2.62±0.45(P<0.005),B40为2.55±0.33(P<0.001),B80为2.48±0.48(P<0.01);P40为6.49±1.12(P<0.001)。(摘要截断于250字)

相似文献

1
A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol.一项评估单次剂量倍他洛尔β-肾上腺素受体选择性的剂量范围研究。
Br J Clin Pharmacol. 1990 Jul;30(1):119-26. doi: 10.1111/j.1365-2125.1990.tb03751.x.
2
The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.时间和剂量对倍他洛尔和美托洛尔相对β1及β2肾上腺素能受体拮抗作用的影响。
Br J Clin Pharmacol. 1991 Feb;31(2):154-9. doi: 10.1111/j.1365-2125.1991.tb05504.x.
3
The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.慢性给药对倍他洛尔和美托洛尔β1及β2肾上腺素能受体拮抗作用的影响。
Eur J Clin Pharmacol. 1991;40(5):467-71. doi: 10.1007/BF00315224.
4
A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.一项评估比索洛尔β1肾上腺素能受体选择性的剂量范围研究。
Eur J Clin Pharmacol. 1991;40(2):135-9. doi: 10.1007/BF00280067.
5
A comparison of the cardioselectivity of five beta-adrenoceptor blocking drugs.五种β-肾上腺素能受体阻断药物的心脏选择性比较。
J Cardiovasc Pharmacol. 1987 Aug;10(2):228-37. doi: 10.1097/00005344-198708000-00014.
6
Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.倍他洛尔、普萘洛尔和阿替洛尔对异丙肾上腺素诱导的β-肾上腺素能受体反应的影响。
Clin Pharmacol Ther. 1985 Nov;38(5):554-9. doi: 10.1038/clpt.1985.223.
7
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.ICI 141,292对人体运动性心动过速及异丙肾上腺素诱导的β-肾上腺素能受体反应的影响。
Br J Clin Pharmacol. 1986 Mar;21(3):249-58. doi: 10.1111/j.1365-2125.1986.tb05187.x.
8
The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.长效β-肾上腺素能受体阻断药H-I 42 BS对人体β-肾上腺素能受体阻断活性及心脏选择性的评估。
Br J Clin Pharmacol. 1987 Apr;23(4):411-23. doi: 10.1111/j.1365-2125.1987.tb03070.x.
9
Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.静脉输注异丙肾上腺素对人体生理性手指震颤的增强作用:评估其在β-肾上腺素能受体拮抗剂评估中的作用。
Br J Clin Pharmacol. 1984 Aug;18(2):145-52. doi: 10.1111/j.1365-2125.1984.tb02446.x.
10
Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.福莫特罗和沙美特罗的β2肾上腺素能受体激动剂/拮抗剂活性评估。
Thorax. 1996 Jan;51(1):54-8. doi: 10.1136/thx.51.1.54.

引用本文的文献

1
Superior oblique myokymia--a topical solution?上斜肌肌纤维颤搐——一种局部治疗方法?
Br J Ophthalmol. 1994 Nov;78(11):882. doi: 10.1136/bjo.78.11.882.
2
The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.时间和剂量对倍他洛尔和美托洛尔相对β1及β2肾上腺素能受体拮抗作用的影响。
Br J Clin Pharmacol. 1991 Feb;31(2):154-9. doi: 10.1111/j.1365-2125.1991.tb05504.x.
3
The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.慢性给药对倍他洛尔和美托洛尔β1及β2肾上腺素能受体拮抗作用的影响。
Eur J Clin Pharmacol. 1991;40(5):467-71. doi: 10.1007/BF00315224.

本文引用的文献

1
Venous occlusion plethysmography.静脉阻塞体积描记法
Methods Med Res. 1960;8:293-301.
2
Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects.阿替洛尔、美托洛尔和普萘洛尔对正常受试者异丙肾上腺素诱发的震颤和心动过速的影响。
Clin Pharmacol Ther. 1981 Apr;29(4):425-33. doi: 10.1038/clpt.1981.59.
3
Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.静脉输注异丙肾上腺素对人体生理性手指震颤的增强作用:评估其在β-肾上腺素能受体拮抗剂评估中的作用。
Br J Clin Pharmacol. 1984 Aug;18(2):145-52. doi: 10.1111/j.1365-2125.1984.tb02446.x.
4
Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation.对优先β-1和β-2肾上腺素能受体刺激的变时性和变力性反应的无创评估。
Clin Pharmacol Ther. 1984 Jun;35(6):776-81. doi: 10.1038/clpt.1984.111.
5
Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.人右心房中β1和β2肾上腺素能受体的共存。通过(±)-[125I]碘氰吲哚洛尔结合进行直接鉴定。
Circ Res. 1983 Dec;53(6):752-8. doi: 10.1161/01.res.53.6.752.
6
A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia.普萘洛尔、普拉洛尔和倍他洛尔(SL75212)对胰岛素诱导的低血糖症的循环和代谢反应的比较。
Eur J Clin Pharmacol. 1981;21(3):177-84. doi: 10.1007/BF00627917.
7
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.心脏选择性β-肾上腺素能受体阻断药倍他洛尔(SL 75212)的疗效及药代动力学观察
Br J Clin Pharmacol. 1981 Feb;11(2):171-80. doi: 10.1111/j.1365-2125.1981.tb01121.x.
8
Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.新型β-肾上腺素能受体拮抗剂倍他洛尔(SL 75212)口服和静脉给药后的血药浓度及药效学效应
Br J Clin Pharmacol. 1980 Nov;10(5):449-52. doi: 10.1111/j.1365-2125.1980.tb01787.x.
9
Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.倍他洛尔(SL 75212)在人体中的β-肾上腺素能受体阻断作用及药代动力学
Br J Clin Pharmacol. 1980 Jul;10(1):41-9. doi: 10.1111/j.1365-2125.1980.tb00500.x.
10
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.单次口服新型β-肾上腺素能受体阻滞剂倍他洛尔(SL 75212)对健康志愿者心血管系统的影响。
Br J Clin Pharmacol. 1980 Jun;9(6):569-75. doi: 10.1111/j.1365-2125.1980.tb01082.x.